Apatinib and Irinotecan Combination as Second-line Treatment in Esophageal Squamous Cell Carcinoma: a Phase I Dose Escalation Study
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Rivoceranib (Primary) ; Irinotecan
- Indications Oesophageal cancer
- Focus Adverse reactions
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 05 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 22 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.